TALVEY
(Talquetamab)Phase 3Monoclonal antibody
Johnson & JohnsonTalquetamab is used to treat multiple myeloma, a type of blood cancer affecting plasma cells. It works by helping the immune system recognize and attack cancer cells.[1] TALVEY is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
TALVEY is one of 122 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.
8
Indications
37
Total Trials
31
Active Trials
121
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
TALVEY
Johnson & JohnsonPhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma24 trials
Show 21 more trials
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Recruiting·—·Phase 2·NCT06505369·50 enrolled
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Recruiting·—·Phase 1·NCT06348108·32 enrolled
Hematological Malignancies2 trials
Multiple Myeloma (MM)2 trials
Daratumumab1 trial
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Recruiting·—·Phase 2·NCT06100237·50 enrolled
7 more indications
Multiple Myeloma in Relapse1 trial
Extramedullary Disease in Multiple Myeloma1 trial
Relapsed/Refractory Multiple Myeloma1 trial
Relapse Multiple Myeloma1 trial
Myeloma Multiple1 trial
Cytokine Release Syndrome1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Aug 9, 2023
TALVEY
BLA BLA761342
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Talquetamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- G-Protein Coupled Receptor Family C Group 5 Member D Binding Agent; T Cell Surface Glycoprotein CD3 Binding Agent[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company